Other agents of interest in MF
| Standard therapies in combination with ruxolitinib . |
|---|
| Danazol |
| ESA |
| Hydroxycarbamide |
| IFN-α (both formulations of pegylated IFN-α) |
| IMiD (thalidomide but pomalidomide and lenalidomide in clinical trials) |
| Radiotherapy (for extramedullary hematopoiesis, bone pain and splenomegaly) |
| Splenectomy |
| SCT |
| Agents either used alone or with ruxolitinib |
| Activin receptor antagonists (sotatercept, luspatercept) |
| Antifibrotic agents (PRM-151 pentraxin analog) |
| CDK4/6 (LEE011) |
| Demethylating agents (azacytidine, decitabine) |
| Drugs acting via apoptosis (LCL-161, navitoclax) |
| Drugs to restore nestin expression (mirabegron) |
| Fedratinib |
| Histone deacetylase inhibitors (panobinostat) |
| Immune checkpoint inhibitors (nivolumab) |
| Itacitinib |
| Pacritinib |
| PI3K/Akt/mTOR inhibitors (BKM120, everolimus) |
| PIM kinase (LGH447 |
| SMO inhibitors (LDE225, glasdegib) |
| Telomerase inhibitors (imetelstat) |
| Type 1 JAKi |
| Standard therapies in combination with ruxolitinib . |
|---|
| Danazol |
| ESA |
| Hydroxycarbamide |
| IFN-α (both formulations of pegylated IFN-α) |
| IMiD (thalidomide but pomalidomide and lenalidomide in clinical trials) |
| Radiotherapy (for extramedullary hematopoiesis, bone pain and splenomegaly) |
| Splenectomy |
| SCT |
| Agents either used alone or with ruxolitinib |
| Activin receptor antagonists (sotatercept, luspatercept) |
| Antifibrotic agents (PRM-151 pentraxin analog) |
| CDK4/6 (LEE011) |
| Demethylating agents (azacytidine, decitabine) |
| Drugs acting via apoptosis (LCL-161, navitoclax) |
| Drugs to restore nestin expression (mirabegron) |
| Fedratinib |
| Histone deacetylase inhibitors (panobinostat) |
| Immune checkpoint inhibitors (nivolumab) |
| Itacitinib |
| Pacritinib |
| PI3K/Akt/mTOR inhibitors (BKM120, everolimus) |
| PIM kinase (LGH447 |
| SMO inhibitors (LDE225, glasdegib) |
| Telomerase inhibitors (imetelstat) |
| Type 1 JAKi |
ESA, erythropoiesis-stimulating agent.